Stilbestrols and stilbestrol derivatives: Estrogenic potency and temporal relationships between estrogen receptor binding and uterine growth

Benita S. Katzenellenbogen, Harriet S. Iwamoto, Daniel F. Heiman, Nancy C. Lan, John A. Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

This study analyzes some of the differences between the estrogenic potencies of two homo logous stilbestrols, the potent estiogen diethylstilbestrol (DES) and the weak estrogen dimethylstilbestrol (DMS). The action of these compounds and their corresponding dimethyl ethers is compared in terms of the duration of their interaction with the estrogen receptor in immature rat uterus and the time-course of responses elicited in this tissue. Dose-response curves of 3-day uterotrophic assays indicate that etherification of DMS, which is only weakly uterotrophic, converts it into a compound, DMS-(OMe)2, that has enhanced uterotrophic activity, while etherification of the more active estrogen, DES, diminishes its potency. Only at high doses is DES-(OMe)2 as effective a uterotrophic agent as DES. After a single injection, DMS (20 μg) and DES (10 μg) both rapidly translocate estrogen receptor from the cytoplasmic to the nuclear compartment, but while uterine weight (by 24 h) and nuclear receptor levels (by 6 h) rapidly return to control levels after DMS, they remain elevated for a more prolonged period after DES. Likewise, DMS stimulates only an early (2 h) wave of uterine deoxyglucose phosphorylation. In contrast to DMS, DMS-(OMe)2 (20 μg) shows a gradual movement of receptor to the nucleus after 1 h, with moderate but above control levels of receptor being maintained for at least 36-48 h. This retention of nuclear receptor correlates with prolonged elevation of uterine weight (beyond 60 h) and stimulation of deoxyglucose metabolism (beyond 24 h). Likewise a high (10 μg) dose of DES-(OMe)2 evokes a slower but more protracted elevation of nuclear receptor levels, and a more prolonged elevation of uterine weight than does DES (10 μg). The weak activity of DMS appears to be due to its short duration of interaction with receptor, and conversion to the methyl ether prolongs nuclear receptor occupancy and increases its biological potency. DES is potent because it is itself long-acting. Methylation of DES further extends its period of nuclear receptor occupancy; this increases its duration of action at high doses, but reduces its potency at low doses.

Original languageEnglish (US)
Pages (from-to)103-113
Number of pages11
JournalMolecular and Cellular Endocrinology
Volume10
Issue number1
DOIs
StatePublished - Jan 1 1978

Fingerprint

Diethylstilbestrol
Estrogen Receptors
Derivatives
Growth
Cytoplasmic and Nuclear Receptors
Level control
Deoxyglucose
Weights and Measures
Estrogens
dimethylstilbestrol
Methyl Ethers
Phosphorylation
Methylation
Metabolism
Uterus
Rats
Assays
Tissue

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this

Stilbestrols and stilbestrol derivatives : Estrogenic potency and temporal relationships between estrogen receptor binding and uterine growth. / Katzenellenbogen, Benita S.; Iwamoto, Harriet S.; Heiman, Daniel F.; Lan, Nancy C.; Katzenellenbogen, John A.

In: Molecular and Cellular Endocrinology, Vol. 10, No. 1, 01.01.1978, p. 103-113.

Research output: Contribution to journalArticle

@article{26f31f98044648f5aab67ebb8868f8ef,
title = "Stilbestrols and stilbestrol derivatives: Estrogenic potency and temporal relationships between estrogen receptor binding and uterine growth",
abstract = "This study analyzes some of the differences between the estrogenic potencies of two homo logous stilbestrols, the potent estiogen diethylstilbestrol (DES) and the weak estrogen dimethylstilbestrol (DMS). The action of these compounds and their corresponding dimethyl ethers is compared in terms of the duration of their interaction with the estrogen receptor in immature rat uterus and the time-course of responses elicited in this tissue. Dose-response curves of 3-day uterotrophic assays indicate that etherification of DMS, which is only weakly uterotrophic, converts it into a compound, DMS-(OMe)2, that has enhanced uterotrophic activity, while etherification of the more active estrogen, DES, diminishes its potency. Only at high doses is DES-(OMe)2 as effective a uterotrophic agent as DES. After a single injection, DMS (20 μg) and DES (10 μg) both rapidly translocate estrogen receptor from the cytoplasmic to the nuclear compartment, but while uterine weight (by 24 h) and nuclear receptor levels (by 6 h) rapidly return to control levels after DMS, they remain elevated for a more prolonged period after DES. Likewise, DMS stimulates only an early (2 h) wave of uterine deoxyglucose phosphorylation. In contrast to DMS, DMS-(OMe)2 (20 μg) shows a gradual movement of receptor to the nucleus after 1 h, with moderate but above control levels of receptor being maintained for at least 36-48 h. This retention of nuclear receptor correlates with prolonged elevation of uterine weight (beyond 60 h) and stimulation of deoxyglucose metabolism (beyond 24 h). Likewise a high (10 μg) dose of DES-(OMe)2 evokes a slower but more protracted elevation of nuclear receptor levels, and a more prolonged elevation of uterine weight than does DES (10 μg). The weak activity of DMS appears to be due to its short duration of interaction with receptor, and conversion to the methyl ether prolongs nuclear receptor occupancy and increases its biological potency. DES is potent because it is itself long-acting. Methylation of DES further extends its period of nuclear receptor occupancy; this increases its duration of action at high doses, but reduces its potency at low doses.",
author = "Katzenellenbogen, {Benita S.} and Iwamoto, {Harriet S.} and Heiman, {Daniel F.} and Lan, {Nancy C.} and Katzenellenbogen, {John A.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1016/0303-7207(78)90063-1",
language = "English (US)",
volume = "10",
pages = "103--113",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Stilbestrols and stilbestrol derivatives

T2 - Estrogenic potency and temporal relationships between estrogen receptor binding and uterine growth

AU - Katzenellenbogen, Benita S.

AU - Iwamoto, Harriet S.

AU - Heiman, Daniel F.

AU - Lan, Nancy C.

AU - Katzenellenbogen, John A.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - This study analyzes some of the differences between the estrogenic potencies of two homo logous stilbestrols, the potent estiogen diethylstilbestrol (DES) and the weak estrogen dimethylstilbestrol (DMS). The action of these compounds and their corresponding dimethyl ethers is compared in terms of the duration of their interaction with the estrogen receptor in immature rat uterus and the time-course of responses elicited in this tissue. Dose-response curves of 3-day uterotrophic assays indicate that etherification of DMS, which is only weakly uterotrophic, converts it into a compound, DMS-(OMe)2, that has enhanced uterotrophic activity, while etherification of the more active estrogen, DES, diminishes its potency. Only at high doses is DES-(OMe)2 as effective a uterotrophic agent as DES. After a single injection, DMS (20 μg) and DES (10 μg) both rapidly translocate estrogen receptor from the cytoplasmic to the nuclear compartment, but while uterine weight (by 24 h) and nuclear receptor levels (by 6 h) rapidly return to control levels after DMS, they remain elevated for a more prolonged period after DES. Likewise, DMS stimulates only an early (2 h) wave of uterine deoxyglucose phosphorylation. In contrast to DMS, DMS-(OMe)2 (20 μg) shows a gradual movement of receptor to the nucleus after 1 h, with moderate but above control levels of receptor being maintained for at least 36-48 h. This retention of nuclear receptor correlates with prolonged elevation of uterine weight (beyond 60 h) and stimulation of deoxyglucose metabolism (beyond 24 h). Likewise a high (10 μg) dose of DES-(OMe)2 evokes a slower but more protracted elevation of nuclear receptor levels, and a more prolonged elevation of uterine weight than does DES (10 μg). The weak activity of DMS appears to be due to its short duration of interaction with receptor, and conversion to the methyl ether prolongs nuclear receptor occupancy and increases its biological potency. DES is potent because it is itself long-acting. Methylation of DES further extends its period of nuclear receptor occupancy; this increases its duration of action at high doses, but reduces its potency at low doses.

AB - This study analyzes some of the differences between the estrogenic potencies of two homo logous stilbestrols, the potent estiogen diethylstilbestrol (DES) and the weak estrogen dimethylstilbestrol (DMS). The action of these compounds and their corresponding dimethyl ethers is compared in terms of the duration of their interaction with the estrogen receptor in immature rat uterus and the time-course of responses elicited in this tissue. Dose-response curves of 3-day uterotrophic assays indicate that etherification of DMS, which is only weakly uterotrophic, converts it into a compound, DMS-(OMe)2, that has enhanced uterotrophic activity, while etherification of the more active estrogen, DES, diminishes its potency. Only at high doses is DES-(OMe)2 as effective a uterotrophic agent as DES. After a single injection, DMS (20 μg) and DES (10 μg) both rapidly translocate estrogen receptor from the cytoplasmic to the nuclear compartment, but while uterine weight (by 24 h) and nuclear receptor levels (by 6 h) rapidly return to control levels after DMS, they remain elevated for a more prolonged period after DES. Likewise, DMS stimulates only an early (2 h) wave of uterine deoxyglucose phosphorylation. In contrast to DMS, DMS-(OMe)2 (20 μg) shows a gradual movement of receptor to the nucleus after 1 h, with moderate but above control levels of receptor being maintained for at least 36-48 h. This retention of nuclear receptor correlates with prolonged elevation of uterine weight (beyond 60 h) and stimulation of deoxyglucose metabolism (beyond 24 h). Likewise a high (10 μg) dose of DES-(OMe)2 evokes a slower but more protracted elevation of nuclear receptor levels, and a more prolonged elevation of uterine weight than does DES (10 μg). The weak activity of DMS appears to be due to its short duration of interaction with receptor, and conversion to the methyl ether prolongs nuclear receptor occupancy and increases its biological potency. DES is potent because it is itself long-acting. Methylation of DES further extends its period of nuclear receptor occupancy; this increases its duration of action at high doses, but reduces its potency at low doses.

UR - http://www.scopus.com/inward/record.url?scp=0017936361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017936361&partnerID=8YFLogxK

U2 - 10.1016/0303-7207(78)90063-1

DO - 10.1016/0303-7207(78)90063-1

M3 - Article

C2 - 564791

AN - SCOPUS:0017936361

VL - 10

SP - 103

EP - 113

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1

ER -